LogicBio Therapeutics

Edit info

Founded: 2014

Location: Lexington, MA

Employee range: 50 - 200

Clinical stage: Clin1/Clin2

Therapy area: Genetic diseases

Drug types: GEN, RAR, PED

Lead product: GeneRide platform

Funding: $48M stock Oct 2020; $80.5M IPO Oct 2018; $45M B Jun 2017; $4M Jan 2016

logicbio.com

linkedin.com

job board

Business:

Gene Therapy

Drug notes:

Also sAAVy platform

About:

LogicBio Therapeutics is developing genetic medicines to fight against rare pediatric diseases. LogicBio is pioneering safer, site-specific genome editing technology to provide durable therapies using their GeneRide proprietary platform. LogicBio has currently designed GeneRide to identify liver-targeted therapies - the platform uses a synthetic viral vector to deliver the corrective transgene to a patient's cell into the highly-expressed albumin locus. By using a 2A peptide, both the corrective transgene and albumin are produced as separate protein products and modify albumin with a small tag to monitor GeneRide activity. LogicBio’s initial product candidates will address diseases by targeting the liver, but the company is looking to expand to other tissues.